Presentation is loading. Please wait.

Presentation is loading. Please wait.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.

Published byKelley Rogers Modified over 9 years ago

Similar presentations

Presentation on theme: "Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent."— Presentation transcript:

1 Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) Presented By Mario Sznol at 2014 ASCO Annual Meeting

2 Disclosures Presented By Mario Sznol at 2014 ASCO Annual Meeting

3 Ipilimumab and Nivolumab Clinical Experience in Patients with Advanced Melanoma Presented By Mario Sznol at 2014 ASCO Annual Meeting

4 Objectives Presented By Mario Sznol at 2014 ASCO Annual Meeting

5 CA209-004 Phase I Study: Dose Cohorts Presented By Mario Sznol at 2014 ASCO Annual Meeting

6 Patient Demographics Presented By Mario Sznol at 2014 ASCO Annual Meeting

7 Activity Summary: Concurrent and Sequenced Cohorts from 004 Presented By Mario Sznol at 2014 ASCO Annual Meeting

8 Response in Target Lesions Presented By Mario Sznol at 2014 ASCO Annual Meeting

9 Slide 9 Presented By Mario Sznol at 2014 ASCO Annual Meeting

10 Characteristics of Response Presented By Mario Sznol at 2014 ASCO Annual Meeting

11 Safety Overview Presented By Mario Sznol at 2014 ASCO Annual Meeting

12 ORR by BRAF Status for Concurrent Cohorts Presented By Mario Sznol at 2014 ASCO Annual Meeting

13 ORR by PD-L1 Status (5% cutoff) Presented By Mario Sznol at 2014 ASCO Annual Meeting

14 ORR by Ipilimumab Exposure at Time of Nivolumab Treatment Presented By Mario Sznol at 2014 ASCO Annual Meeting

15 Overall Survival for Concurrent Therapy by Dose Cohort Presented By Mario Sznol at 2014 ASCO Annual Meeting

16 Survival Endpoints for Concurrent and Sequential Therapy by Dose Cohort Presented By Mario Sznol at 2014 ASCO Annual Meeting

17 Conclusions Presented By Mario Sznol at 2014 ASCO Annual Meeting

18 Acknowledgments Presented By Mario Sznol at 2014 ASCO Annual Meeting

Download ppt "Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent."

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Antoni Ribas, M.D., Ph.D. Professor of Medicine Professor of Surgery

Antoni Ribas, M.D., Ph.D. Professor of Medicine Professor of Surgery
Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.
Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.

Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.
Should BRAF inhibitors be continued ‘beyond progression’? Is there a rationale for discontinuous dosing of BRAF inhibitors? Is there a rationale for alternation.

Should BRAF inhibitors be continued ‘beyond progression’? Is there a rationale for discontinuous dosing of BRAF inhibitors? Is there a rationale for alternation.
Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Selezione dei pazienti affetti da melanoma Vanna Chiarion Sileni Melanoma and Skin Cancer Unit IOV-IRCCS, Padova.

Selezione dei pazienti affetti da melanoma Vanna Chiarion Sileni Melanoma and Skin Cancer Unit IOV-IRCCS, Padova.
Immunotherapy is the Preferred Initial Treatment for Most Patients with Metastatic BRAF V600 Mutant Melanoma Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi.

Immunotherapy is the Preferred Initial Treatment for Most Patients with Metastatic BRAF V600 Mutant Melanoma Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation 1 Phase III Randomized, Open-Label, Multicenter Trial (BRIM3) Comparing BRAF Inhibitor.

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation 1 Phase III Randomized, Open-Label, Multicenter Trial (BRIM3) Comparing BRAF Inhibitor.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib.

Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib.
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

Similar presentations

Ads by Google